Tonix Pharmaceuticals Holding Corp. (TNXP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tonix Pharmaceuticals Holding Corp. (TNXP) closed at USD 6.40 on 2026-10-14, a change of -67.2 % over the past year, with a market capitalization of USD 110.11M.

Tonix Pharmaceuticals Holding Corp. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tonix Pharmaceuticals Holding Corp. key figures

Previous close

USD 6.40 (2026-10-14)

1-year change

-67.2 %

Market cap

USD 110.11M

Enterprise value

USD -64.85M

P/E ratio (trailing)

-0.49

P/E ratio (forward)

-0.82

EPS (trailing)

-13.06

EPS (forward)

-7.88

PEG ratio

n/a

Price to book

0.49

Revenue growth

577.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.71

Employees

142

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tonix Pharmaceuticals Holding Corp. and compare it with other stocks.